Design and Synthesis of an Aniline Derivative with Biological Activity on Heart Failure-Reference-Cited by-同舟云学术

Design and Synthesis of an Aniline Derivative with Biological Activity on Heart Failure

Published:2021-02-11 Issue:2 Volume:24 Page:220-232
ISSN:1386-2073
Container-title:Combinatorial Chemistry & High Throughput Screening
language:en
Short-container-title:CCHTS

Author:

Alejandra Garcimarero-Espino E.¹^ORCID,Lauro Figueroa-Valverde²,Marcela Rosas-Nexticapa³^ORCID,Maria Lopez-Ramos²^ORCID,Francisco Diaz Cedillo⁴^ORCID,Virginia Mateu-Armand³,Yazmin Ortiz-Ake²^ORCID

Affiliation:

1. Facultad de Medicina, Universidad Veracruzana. Médicos y Odontólogos s/n, 91010, Xalapa, Veracruz, Mexico

2. Laboratory of Pharmaco-Chemistry at the Faculty of Chemical Biological Sciences of the University Autonomous of Campeche, Av. Ex Hacienda Kala s/n, 24085 San Francisco de Campeche, Campeche, Mexico

3. Facultad de Nutricion, Universidad Veracruzana. Medicos y Odontologos s/n, 91010, Xalapa, Veracruz, Mexico

4. Escuela Nacional de Ciencias Biologicas del Instituto Politecnico Nacional. Prol. Carpio y Plan de Ayala s/n Col. Santo Tomas, Mexico

Abstract

Background: Several compounds have been synthesized as a therapeutic alternative for heart failure; however, its preparation requires special conditions. Objective: The aim of this study, was to synthesize some aniline derivatives (4-9) from 3- ethynylaniline to evaluate their biological activity against heart failure. Methods: The synthesis of aniline derivatives involved a series of reactions such as etherification, addition, and cyclization. The structure of all compounds obtained was confirmed by spectroscopic and spectrometric methods. In addition, to evaluate the biological activity of compounds, an ischemia/reperfusion injury model was used. Results: The results showed that compound 8 decreases heart failure, which translates into a decrease in the infarction area compared to compounds 4-7 and 9. Conclusion: This study reports a facile method for the preparation of aniline derivatives. This method offers some advantages such as; a simple procedure, low cost, and easy work up. In addition, compound 8 showed an interesting biological activity against heart failure. This phenomenon is particularly interesting because the biological activity induced by this compound could involve a molecular mechanism that is different from other drugs used for the treatment of heart failure.

Publisher

Bentham Science Publishers Ltd.

Subject

Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine

Reference46 articles.

1. Lawson C.A.; Zaccardi F.; Squire I.; Okhai H.; Davies M.; Huang W.; Mamas M.; Lam C.S.P.; Khunti K.; Kadam U.T.; Risk factors for heart failure: 20-year population-based trends by sex, socioeconomic status, and ethnicity. Circ Heart Fail 2020,13(2)

2. Yu Y.; Gupta A.; Wu C.; Masoudi F.A.; Du X.; Zhang J.; Krumholz H.M.; Li J.; China PEACE Collaborative Group. Characteristics, management, and outcomes of patients hospitalized for heart failure in China: The China PEACE retrospective heart failure study. J Am Heart Assoc 2019,8(17)

3. Kim T.H.; Yang P.S.; Uhm J.S.; Kim J.Y.; Pak H.N.; Lee M.H.; Joung B.; Lip G.Y.H.; CHA2DS2-VASc score (congestive heart failure, hypertension, age≥ 75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65–74, female) for stroke in Asian patients with atrial fibrillation: a Korean nationwide sample cohort study. Stroke 2017,48(6),1524-1530

4. Velazquez E.J.; Morrow D.A.; DeVore A.D.; Duffy C.I.; Ambrosy A.P.; McCague K.; Rocha R.; Braunwald E.; PIONEER-HF Investigators Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019,380(6),539-548

5. Kenchaiah S.; Evans J.C.; Levy D.; Wilson P.W.; Benjamin E.J.; Larson M.G.; Kannel W.B.; Vasan R.S.; Obesity and the risk of heart failure. N Engl J Med 2002,347(5),305-313